Novo's pill will also be sold in 9 mg and a higher long-term dose of 25 mg
Treatment with febuxostat did not reduce significantly the progression renal disease, with a fall in eGFR in the placebo group of (-0.47 4.48 ml/min/1.73 m2) vs 0.23 5.26 ml/min/1.73 m2 in the febuxostat group
We strive to provide the most effective, scientifically-backed treatments to our patients
Metabolism and nutritional disorders were the third most commonly reported AEs, mainly in the form of decreased appetite, occurring in 80% (20/25) of subjects
In 2026 there are oral weight-loss pills about to be approved by the FDA
The drug can cross the blood-brain barrier (BBB) and activate GLP-1R in the CNS [49, 50], thus producing neuroprotective and anti-inflammatory effects [50,51,52,53,54,55]